InvestorsObserver is giving Salarius Pharmaceuticals Inc (SLRX) an Analyst Rating Rank of 81, meaning SLRX is ranked higher by analysts than 81% of stocks. The average projection by analysts for SLRX is $3.8 over the next 12 months and analyst’s classify the stock as a Strong Buy
Why are Analyst Ratings Important?
Fundamental research of the underlying health of a company can be an extremely useful resource when making investment decisions. Analysts observe growth prospects and forecasted earnings of companies to gain a comprehensive view of particular industries. This data allows traders to react before numbers are officially reported.
Investors Observer takes the ratings from these analysts and percentile ranks those aveages. This allows you to compare stocks extensively and in more detail than the common buy/hold/sell ratings.
What's Happening With Salarius Pharmaceuticals Inc Stock Today?
Salarius Pharmaceuticals Inc (SLRX) stock is trading at $1.20 as of 10:19 AM on Wednesday, May 20, an increase of $0.03, or 2.14% from the previous closing price of $1.17. The stock has traded between $1.15 and $1.33 so far today. Volume today is elevated. So far 970,751 shares have traded compared to average volume of 513,234 shares.
